Fig. 1

HV-107 inhibits Rac activity in breast cancer cell lines. To examine the effects of HV-107 on MDA-MB-231 (A–D) and MDA-MB-468 (E–H) triple negative breast cancer cells, a 24-h treatment with HV-107 ranging from 0 to 2000 nM was conducted. Pulldown assays utilizing the p21-binding domain of PAK were employed to isolate the active form of Rac (GTP bound), followed by western blot analysis. The western blot images presented in panels A and E illustrate the levels of both total Rac and GTP-bound Rac in MDA-MB-231 and MDA-MB-468 cells treated with various concentrations of HV-107. The quantification of total Rac levels is depicted in panels B and F, while the quantification of GTP-bound Rac levels is shown in panels C and G. Panels D and H represent the ratio of GTP-bound Rac to total Rac levels. I, J Pulldowns with RacG15A beads followed by western blots were performed to investigate Rac-Vav2 binding capacity in response to 250 nM HV-107. The western blot images and quantifications depict the levels of Vav2 bound to the RacG15A beads. Actin was used as a loading control. N = 3–4. Error bars represent ± SEM; * p ≤ 0.05